(Q41126458)

27 September 2017

title

Genetic engineering of a recombinant fusion possessing anti-tumor F(ab')2 and tumor necrosis factor (English)

1 reference

27 September 2017

Xiang J

1

1 reference

27 September 2017

Moyana T

series ordinal

2

1 reference

27 September 2017

Qi Y

series ordinal

3

1 reference

27 September 2017

publication date

1 February 1997

1 reference

27 September 2017

published in

Journal of Biotechnology

1 reference

27 September 2017

volume

53

1 reference

27 September 2017

issue

1

1 reference

27 September 2017

page(s)

3-12

1 reference

A monoclonal antibody-Pseudomonas toxin conjugate that specifically kills multidrug-resistant cells

27 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1656%2896%2901639-2

7 January 2021

Comparative biological properties of a recombinant chimeric anti-carcinoma mAb and a recombinant aglycosylated variant

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1656%2896%2901639-2

7 January 2021

Phase I study of recombinant human tumor necrosis factor alpha in advanced malignant disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1656%2896%2901639-2

7 January 2021

A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1656%2896%2901639-2

7 January 2021

Genetically engineered immunoglobulins reveal structural features controlling segmental flexibility

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1656%2896%2901639-2

7 January 2021

Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1656%2896%2901639-2

7 January 2021

Recombinant Human Tumor Necrosis Factor Administered as a 24-Hour Intravenous Infusion. A Phase I and Pharmacologic Study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1656%2896%2901639-2

7 January 2021

Production of murine V-human Cr1 chimeric anti-TAG72 antibody using V region cDNA amplified by PCR.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1656%2896%2901639-2

7 January 2021

A genetically engineered single-chain FV/TNF molecule possesses the anti-tumor immunoreactivity of FV as well as the cytotoxic activity of tumor necrosis factor.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1656%2896%2901639-2

7 January 2021

10.1016/S0168-1656(96)01639-2

Identifiers

DOI

1 reference

27 September 2017

1 reference